Lancet retatrutide trial reports 23% weight loss in type 2 diabetes
Eli Lilly has not filed the triple agonist with the FDA and says it plans to submit next year.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 30 14:45 ETSource: WFTV
The wire
- 01A Lancet trial of more than 1,110 patients with type 2 diabetes, average weight 234 pounds and BMI near 38, reported up to 60 pounds lost, about 23%, over 80 weeks.
- 02Retatrutide targets GLP-1, GIP and glucagon receptors; reported loss exceeds the 10% to 15% range cited for semaglutide and tirzepatide in diabetes trials.
- 03Side effects included diarrhea and nausea, and seven deaths occurred during the trial, which investigators said were unrelated; no FDA submission has been made yet.
From the source
Read at wftv.comRetatrutide: New drug shows weight loss promise
Another drug may soon hit the market to help battle obesity.
